Anti-EMR1 CAR-T cell therapy - Humanigen
Alternative Names: Anti-EMR1 immunotherapy; EMR1-CAR-T; HGEN 005 anti-EMR1 CAR-T cell therapyLatest Information Update: 28 Jul 2022
At a glance
- Originator Humanigen
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Leukaemia
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Leukaemia in USA (Parenteral)
- 22 Jun 2018 Preclinical trials in Leukaemia in USA (Parenteral), prior to June 2018 (Humanigen pipeline, June 2018)